RS Pharmaceutical Innovations evolved from the expertise applied in the field of nutritional biochemistry, metabolic supplemental interventions through blood plasma amino acid analysis.  It is from this thorough understanding of metabolism and its mechanisms that we formulate and manufacture effective and result driven FOCUSCARE™ for optimum health and well-being leading to improved skin care. We also utilize this understanding to apply behavioral theory-based research to access the mechanisms of how attitudes and beliefs related to diet and how health influences behavior in general.

Nutritional biochemistry is an applied scientific study, which is based on biology and chemistry, put together with the science of nutrition. Through the understanding of metabolism of living organisms and chemical analysis at the molecular level, we are able to discover the nutritionally beneficial materials from which functional foods are derived alongside their chemical application and development.
 

Specifically, we examine scientific research publications where mechanisms through genetic cell-line experiments were used and also apply biochemical research analysis in order to determine the components and effects of newly found materials.

 

Ian Roothman , Founder

BSc Biochemistry, Physiology (Univ of Pretoria)

MCSD (Microsoft Certified Solutions Developer)

Worldwide, people of all ages are recognizing that health and happiness go hand in hand with good nutrition, moderate exercise, and a healthy lifestyle. At Roothman Specialised Pharmaceutical Innovations we believe that nutrition plays a vital role in managing and preventing disease. 

 

Historically the human race has had to rely upon a healthy eating and nutritional intake to help the body's immune system fight off various forms of infectious disease. In today's highly stressed world, chronic ailments such as cancer, diabetes, and cardiovascular disease have become more prevalent and as such a healthy diet has become the virtue of the modern generation. 

 

We are proud to be at the forefront of studies and research into reversing or eliminating chronic disease and nutritional disorders for both the general public as well as sportsmen and women in the highly competitive sporting environment. 

 

We are committed to providing all of our clients with best we can offer them towards their pursuit of a healthy lifestyle through the addition of nutritional supplementation that will help to ensure optimal health and performance on all human endeavor.

 

References

1. Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog Biophys Mol Biol. 2006 Sep;92(1):65-79.

2. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5.

3. Martini LA, Wood RJ. Vitamin D status and the metabolic syndrome. Nutr Rev. 2006 Nov;64(11):479-86.

4. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome ‘X’? Br J Nutr. 1998 Apr;79(4):315-27.

5. Achinger SG, Ayus JC. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl. 2005 Jun;(95):S37-S42.

6. Ridge BD, Batt MD, Palmer HE, Jarrett A. The dansyl chloride technique for stratum corneum renewal as an indicator of changes in epidermal mitotic activity following topical treatment. Br J Dermatol. 1988 Feb;118(2):167-74.

7. Chapellier B, Mark M, Messaddeq N, et al. Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. EMBO J. 2002 Jul 1;21(13):3402-13.

8. Koussoulakos S, Sharma KK, Anton HJ. Effect of vit A on wound epidermis during forelimb regeneration in adult newts. Int J Dev Biol. 1990 Dec;34(4):433-9].

9. Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. Altern Med Rev. 1999 Aug;4(4):249-65.

10. Nocerino E, Amato M, Izzo AA. The aphrodisiac and adaptogenic properties of ginseng. Fitoterapia. 2000 Aug;71 Suppl 1:S1-5.]

11. Salonen JT. Selenium in ischaemic heart disease. Int J Epidemiol, 1987 Jun, 16:2, 323-8.

12. Paolisso G, et al. Primary and secondary prevention of atherosclerosis: is there a role for antioxidants? Diabetes Metab, 1999 Sep, 25:4, 298-306.

13. Hercberg S, et al. "The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. Supplementation on VItamines et Minéraux AntioXydants. Food Chem Toxicol, 1999 Sep, 37:9-10, 925-30.

14. 170. Paolisso G, et al. Primary and secondary prevention of atherosclerosis: is there a role for antioxidants? Diabetes Metab 1999 Sep;25(4):298-306.

15. Neve J. Selenium and cardiovascular pathology. Source Pathol Biol (Paris), 1989 Dec, 37:10, 1102-6.

16. Dubois F, et al. [Selenium: physiologic role and value in human pathology]Pathol Biol (Paris), 1988 Oct, 36:8, 1017-25.

17. Virtamo J, et al. Serum selenium and the risk of coronary heart disease and stroke. Source Am J Epidemiol, 1985 Aug, 122:2, 276-82.

18. Kok FJ, et al. Selenium status and chronic disease mortality: Dutch epidemiological findings. Int J Epidemiol, 1987 Jun, 16:2, 329-32.

19. Ringstad J, et al. The TromsI Heart Study: serum selenium in a low-risk population for cardiovascular disease and cancer and matched controls. Ann Clin Res, 1987, 19:5, 351-4.

20. Baum MK, et al. High risk of HIV-related mortality is associated with selenium deficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1997 Aug.

21. Baum MK, et al. Micronutrient status in relationship to mortality in HIV-1 disease. Nutr Rev 1998 Jan;56(1 Pt 2):S135-9.

22. Look MP, et al. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in

asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr. 1997 Apr;51(4):266-72.

23. Periquet BA, et al. Micronutrient levels in HIV-1-infected children. AIDS, 1995 Aug, 9:8, 887-93.

24. Hori K, et al. Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses, 1997 Oct, 13:15, 1325-32.

25. McCarty MF. natural antimutagenic agents may prolong efficacy of human immunodeficiency virus drug therapy. Med Hypotheses, 1997 Mar, 48:3, 215-20.

26. Cirelli A, et al. Serum selenium concentration and disease progress in patients with HIV infection. Clin Biochem, 1991 Apr, 24:2, 211-4. Look MP, et al. Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr, 1997 Apr, 51:4, 266-72.

27. Constans J, et al. Selenium and HIV infection [editorial] Nutrition, 1999 Sep, 15:9, 719-20.

28. Olmsted L, et al. Selenium supplementation of symptomatic human immunodeficiency virus infected patients. Biol Trace Elem Res, 1989 Apr, 20:1-2, 59-65.

29. Taylor EW, et al. Genomic structures of viral agents in relation to the biosynthesis of selenoproteins. Biol Trace Elem Res, 1997 Jan, 56:1, 63-91.

30. Sappey C, et al. Vitamin, trace element and peroxide status in HIV seropositive patients: asymptomatic patients present a severe beta-carotene deficiency. Clin Chim Acta 1994 Oct 14;230(1):35-42.

31. Patrick L. Nutrients and HIV: part two--vitamins A and E, zinc, B-vitamins, and magnesium. Altern Med Rev 2000 Feb;5(1):39-51.

32. Constans J, et al. Selenium and HIV infection. Nutrition 1999 Sep;15(9):719-20.

33. May SW, et al. Selenium-based antihypertensives. Rationale and potential. Drugs 1998 Dec;56(6):959-64.

34. Rabaud C, et al. [Free radicals and HIV infection]. Ann Biol Clin (Paris) 1997 Nov-Dec;55(6):565-71.

35. Brown NA, et al. Nutrition supplements and the eye. Eye 1998;12 ( Pt 1):127-33.

36. 226. Sperduto RD, et al. The Linxian cataract studies. Two nutrition intervention trials. Arch Ophthalmol 1993 Sep;111(9):1246-53.

37. Knekt P, et al. Serum antioxidant vitamins and risk of cataract. BMJ 1992 Dec 5;305(6866):1392-4.

38. Remarkable success of antioxidant treatment (selenomethionine and vitamin E) to a 34-year old patient with posterior subcapsular cataract, keratoconus, severe atopic eczema and asthma. Acta Ophthalmol (Copenh), 1988 Apr, 66:2, 237-8.

39. Karaküçük S, et al. Selenium concentrations in serum, lens and aqueous humour of patients with senile cataract. Acta Ophthalmol Scand, 1995 Aug, 73:4, 329-32.

40. Duffield A.J., et al. An estimation of selenium requirements for New Zealanders American Journal of Clinical Nutrition 1999, 70/5 (896-903).

41. Prasad K.N, et al. Multiple antioxidants in the prevention and treatment of Parkinson's disease. Journal of the American College of Nutrition 1999, 18/5 (413-423).

42. Angstwurm M.W.A, et al. Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Critical Care Medicine 1999, 27/9(1807-1813).

43. Caspi O, et al. Parkinson's disease: "Don't become your disease!" Integrative Medicine 1999, 2/1 (37-42).

44. Geerling B.J., et al. Nutrition and inflammatory bowel disease: An update Scandinavian Journal of Gastroenterology, Norway) 1999, 33/230 (95-105).

45. Metnitz P.G.H., et al. Antioxidant status in patients with acute respiratory distress syndrome. Intensive Care Medicine (Germany) 1999, 25/2 (180-185).

46. Kuettner A, Pieper A, Koch J, Enzmann F, Schroeder S. Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOACT study. Int J Cardiol. 2005 Feb 28;98(3):413-9.

47. Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol Aspects Med. 1994;15 Suppls165-75.

48. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.

49. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer’s and Parkinson’s diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr. 2004 Aug;36(4):381-6.

50. Baker SK, Tarnopolsky MA. Targeting cellular energy production in neurological disorders. Expert Opin Investig Drugs. 2003 Oct;12(10):1655-79.

51. Horton et al. Principles of Biochemistry, 3rd edition, 2002

52. Simon H. The immunology of exercise: a brief review

53. Bounos G, et al. The immuno enhancing property of dietary whey protein concentrate. Clinical and Investigational Medicine 11: 271-278, 1988.

54. Bounus G, et al. Immuno enhancing property of dietary whey protein in mice: role of gluthathione. Clinical and Investigational Medicine 12: 154-161,1989.

55. Bounos G, et al. Dietary whey protein inhibits the development of dimethylhydrazine-induced malignancy. Clinical and Investigational Medicine 11: 213-217, 1988.

56. Bounous G, et al. The biological activity of undenatured dietary whey proteins: role of gluthatione. Clin Invest Med, 1991;14:296-309.4

PROUDLY DISTRIBUTED BY

DISCLAIMER
This product is not intended to diagnose, treat, cure or prevent any disease. Individual results will vary.

Privacy Policy  |  Terms & Conditions

Copyright © RS Pharmaceutical Innovations . All Rights Reserved